TheraRadar
Clinical-Stage Companies / Alvotech Swiss

Alvotech Swiss

Pre-Approval PRO BETA
20
Total Trials
10
Phase 3
0
Phase 2
1
Recruiting
190
Score

Pipeline by Phase

Phase 3
10
Phase 2
Phase 1
10

Therapeutic Focus

Psoriasis Healthy Volunteers Plaque Psoriasis Diabetic Macular Edema Melanoma

Clinical Trials (20)

NCT07489131 Phase 3 RECRUITING

Clinical Study to Compare Efficacy and Safety of AVT29 and Eylea HD in Participants With Diabetic Macular Edema

Started: 4/22/2026

NCT06570772 Phase 3 TERMINATED

Study to Investigate Comparative Efficacy, Safety and Immunogenicity Between AVT16 and Entyvio

Started: 9/23/2024

NCT05395091 Phase 3 COMPLETED

Multicenter Study in Postmenopausal Women With Osteoporosis, ALVOBOND

Started: 8/23/2022

NCT05986786 Phase 3 COMPLETED

Clinical Study to Evaluate the Handling and Safety of AVT06 PFS in Subjects With Chorioretinal Vascular Disease

Started: 2/28/2024

NCT05842213 Phase 3 COMPLETED

Comparative, Multicenter Study in Subjects with Rheumatoid Arthritis, ALVOFLEX

Started: 3/30/2023

NCT05155293 Phase 3 COMPLETED

Clinical Study to Compare Efficacy and Safety of AVT06 and EU-Eylea (ALVOEYE)

Started: 6/28/2022

NCT04930042 Phase 3 COMPLETED

Efficacy, Safety, and Immunogenicity of AVT04 With Moderate-to-Severe Chronic Plaque Psoriasis

Started: 6/3/2021

NCT04224194 Phase 3 COMPLETED

Auto-injector Real Life Handling in Patients

Started: 11/4/2019

NCT04453137 Phase 3 COMPLETED

Pharmacokinetic, Efficacy, Safety, and Immunogenicity of AVT02 With Moderate to Severe Chronic Plaque Psoriasis

Started: 6/30/2020

NCT03849404 Phase 3 COMPLETED

Efficacy, Safety, and Immunogenicity of AVT02 With Moderate-to-Severe Chronic Plaque Psoriasis

Started: 2/20/2019

NCT07475572 Phase 1 NOT YET RECRUITING

A Randomized, Double-Blind, Pharmacokinetic Similarity Study to Compare AVT32-DRL_PB With Keytruda® in Participants With Fully Resected Melanoma

Started: 6/19/2026

NCT06732804 Phase 1 COMPLETED

Study to Investigate Comparative Pharmacokinetics, Safety, Immunogenicity and Tolerability Between AVT80 and Entyvio

Started: 2/11/2025

NCT05632211 Phase 1 COMPLETED

A Study to Investigate the PK, Safety, and Tolerability Between AVT05, US and EU Simponi® in Healthy Adult Participants

Started: 12/16/2022

NCT05876949 Phase 1 COMPLETED

AVT03 With Xgeva in Healthy Male Subjects

Started: 7/21/2023

NCT06400719 Phase 1 COMPLETED

Pilot Study of AVT16 in Healthy Adult Subjects

Started: 5/29/2024

NCT05126784 Phase 1 COMPLETED

AVT03 With Prolia in Healthy Male Subjects

Started: 6/29/2022

NCT04744363 Phase 1 COMPLETED

Pharmacokinetics, Safety and Tolerability Study of AVT04 to EU Approved and US Licensed Stelara (Ustekinumab)

Started: 5/25/2021

NCT03849313 Phase 1 COMPLETED

Pharmacokinetics, Safety and Tolerability Study of AVT02 to EU-approved and US-licensed Humira (Adalimumab)

Started: 3/20/2019

NCT03983876 Phase 1 COMPLETED

PK, Safety and Tolerability Study of AVT02 (Adalimumab) Pre-filled Syringe (PFS) vs, AVT02 Autoinjector (AI)

Started: 7/1/2019

NCT03579823 Phase 1 COMPLETED

Comparative Safety, Tolerability, Pharmacokinetic Study of AVT02 (100MG/ML) and Humira (100MG/ML) in Healthy Volunteers

Started: 5/21/2018

Drug Candidates

AVT29 (proposed aflibercept HD biosimilar) Eylea HD (aflibercept HD) AVT32-DRL_PB Keytruda AVT80 Geographical region 1 Entyvio Geographical region 2 Entyvio AVT16 Vedolizumab AVT03
Activity Status: Active
Last Trial Started: 6/19/2026
Last Trial Ended: 1/8/2026
Trials (12 months): 2
Completed Trials: 17
Data sourced from ClinicalTrials.gov. This company has no FDA-approved drugs.